Moderna, Merck cancer vaccine cuts melanoma recurrence 42%, shares fall

· Health · United States

Detailed Phase 3 data show that a personalized mRNA cancer vaccine from Moderna and Merck, combined with the immunotherapy Keytruda, cut the risk of disease recurrence or death by 42% in patients with melanoma compared with standard treatment. The result met the trial's key endpoints, confirming what the companies had signaled was a closely watched readout. Investors nonetheless sold the news: shares of both companies fell as the data, while positive, fell short of the high hopes built into expectations, with one analyst describing a "sell-the-news reaction." The trial is a landmark test of whether mRNA technology can be used therapeutically in cancer, not just preventively in infectious disease. The 42% reduction is now the benchmark against which the program's regulatory path and commercial prospects will be judged.

Why it matters：A working therapeutic mRNA cancer vaccine would validate a platform beyond infectious disease and open a new oncology franchise, so the gap between trial success and investor expectations matters for the whole sector.

Key points

  • The combination cut relapse or death risk by 42% versus standard treatment.
  • Trial met key endpoints but fell short of investor expectations.
  • Shares of both Moderna and Merck declined on the results.

Sources (original reporting)

More stories from this day